Alhosin et al. (2010) demonstrated that thymoquinone successfully inhibited proliferation (IC50 = 24.2 μM after 24 h vs. 23.3 μM after 48 h) and viability (IC50 = 24.3 μM after 24 h vs. 23.1 μM after 48 h) in p53-defected Jurkat lymphoblastic leukemia cells in a dose- and time-dependent manner. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.